Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?

Alexandre Y. Dombrovski, M. D.1, Jill M. Cyranowski, Ph. D.1, Benoit H. Mulsant, M. D.1,2, Patricia R. Houck, M. S.1, Daniel J. Buysse, M. D.1, Carmen Andreescu1, Michael E. Thase1,3,4, Alan G. Mallinger, M.D.1,5, and Ellen Frank, Ph. D.1

1Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine 2Centre for Addictions and Mental Health, and Department of Psychiatry, University of Toronto 3Department of Psychiatry, University of Pennsylvania School of Medicine 4Philadelphia Veterans Affairs Medical Center 5Mood and Anxiety Disorders Program, National Institutes of Health Intramural Research Program, Bethesda, Maryland

Abstract

Background—Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression.

Method—We analyzed data on 131 women aged 20 to 60 from a 2-year randomized trial of weekly vs. twice-monthly vs. monthly IPT-M. Participants achieved remission with IPT alone (n=99) or IPT plus sequential antidepressant medication (n=32). Medications were tapered before starting maintenance treatment. Residual symptoms were assessed with the Hamilton Rating Scale for Depression (HRSD; total score and subscales); insomnia was also assessed in 76 women with the Pittsburgh Sleep Quality Index (PSQI). Data analyses used Cox proportional hazards regression models.

Results—Neither overall burden of residual symptoms (HRSD total score), nor HRSD mood and anxiety subscale scores predicted recurrence during ongoing IPT-M. In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence.
Women with persistent insomnia who required sequential pharamacotherapy had the highest recurrence rate (65%) compared to women requiring sequential treatment without insomnia (13%), or women who had recovered with IPT alone but had persistent insomnia (21%) or no insomnia (18%).

Conclusions—Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication. govIdentifier: NCT00227981

Keywords
Depressive Disorder; Depressive Symptoms; Sleep Initiation and Maintenance Disorders; Sleep; Anxiety; Recurrence

INTRODUCTION

Complete recovery is the goal of depression treatment. However, numerous studies (Judd et al. 1998; Kanai et al. 2003; Karp et al. 2004; Paykel et al. 1995; Thase et al. 1992; Van Londen et al. 1998) and clinical practice show that many of the patients who recover from an episode of depression experience persisting symptoms, which may put them at risk for recurrence. These residual symptoms have been likened to the mirror image of a prodrome, suggesting that the onset and the resolution (“roll-back”) of the depressive episode may be related (Fava 1999). Alternatively, residual symptoms may be seen as long-term psychological sequelae of a depressive episode (“depressive scar hypothesis”) (Shea et al. 1996).

While the negative prognostic significance of residual symptoms has been established, it is unclear how clinicians should approach them. Are certain symptoms more ominous than others and should be targeted preferentially? In older patients with depression, persistent anxiety rather than the core depressive symptoms of low mood, guilt, suicidal thoughts, and anergia/anhedonia herald poorer long-term outcomes (Dombrovski et al. 2007). Persistently poor sleep quality, assessed both objectively (Buysse et al. 1996; Kupfer et al. 1990) and subjectively (Buysse et al. 1996; Reynolds et al. 1997), also appears to be a marker of unfavorable long-term course. The development of sleep problems may also be a prodromal symptom of recurrence (Perlis et al. 1997).

The problem of residual symptoms may be of particular relevance for patients who prefer a psychological treatment to antidepressant medications. A recent study examined rates of residual insomnia following acute treatment with fluoxetine or cognitive behavior therapy (CBT), finding a prevalence of 51%, with no significant differences between the treatments (Carney et al. 2007). To our knowledge, no study has assessed the extent of residual symptoms following acute treatment with another commonly used time-limited therapy for depression, interpersonal psychotherapy (IPT), or, more importantly, their long-term impact.

We recently reported the results of a two-year trial of maintenance interpersonal psychotherapy (IPT) in women aged 20 to 60 with recurrent depression (Frank et al. 2007). Maintenance IPT (IPT-M) therapy sessions, provided at frequencies as low as once per month, were relatively effective in preventing depression recurrence among patients treated to remission with IPT alone; despite having a median of 4 previous episodes, only 26% had a recurrence of depression. IPT-M was less effective for patients who required adjunctive medication treatment to achieve remission of the acute depressive episode; after the medication was tapered, these women displayed a 50% recurrence rate during maintenance treatment. In this study, in addition to replicating and extending previous findings on the long-term impact of residual symptoms (Dombrovski et al. 2007; Flint and Rifat 1997;
Kupfer et al. 1990; Perlis et al. 1997; Reynolds et al. 1997), we had the opportunity to examine the role of these symptoms in two groups of women: those who recovered from depression with psychotherapy alone and those who required the addition of an antidepressant to achieve remission. We hypothesized that participants with higher overall levels of residual symptoms, and persistent anxiety and insomnia in particular, would be more likely to suffer a recurrence.

METHODS

Study design and participant flow

All participants provided written informed consent as required by the University of Pittsburgh Institutional Review Board. Between 1992 and 1999, 233 women aged 20 to 60 and accepting non-pharmacologic treatment for their depression entered the study. All had recurrent major depression diagnosed using the Research Diagnostic Criteria (18) as extracted from either the Schedule for Affective Disorders and Schizophrenia (SADS) (18) or the Structured Clinical Interview for DSM-IV. Participants were required to have a score of 15 or above on the Hamilton Rating Scale for Depression 17-item version (HRSD-17) (Hamilton 1960) and a score 7 or above on the Raskin Severity of Depression Scale. Patients with co-occurring Axis I disorders other than anxiety disorders, hypomania, adult-onset dysthymia, eating disorders (NOS); antisocial or borderline personality disorder; history of alcohol or substance abuse/dependence within the past 2 years; history of a manic episode; or any significant or unstable medical condition were excluded.

In the acute treatment phase participants received weekly IPT alone for 12–24 weeks, or until achieving depression remission, defined as 3 consecutive weeks with an HRSD-17 score ≤ 7. Of 112 patients who achieved remission, 99 remained well for the requisite 5 additional weeks of continuation therapy and were then entered into the maintenance phase. Eighty-six IPT non-responders agreed to the addition of a selective serotonin reuptake inhibitor (SSRI), among whom 58 (67%) remitted. SSRI remitters received an additional 17 weeks of continuation phase treatment, after which the SSRI was tapered over 1 to 4 weeks, followed by 4 to 6 weeks of IPT alone; 32/58 participants remained in stable remission. During the continuation phase, 1/32 women in this group received zolpidem and 2/32, trazodone, for the treatment of insomnia. Thus, 99 women who remitted with IPT alone and 32 who remitted with the IPT/SSRI combined treatment were randomly assigned to one of three frequencies (weekly, twice-monthly, or monthly) of IPT-M sessions for a period of 2 years or until recurrence.

Measures

Recurrence was defined as two consecutive HRSD-17 scores of 15 or more and meeting DSM IV criteria for major depression, confirmed by an independent psychiatrist. We assessed residual symptoms at the time of random assignment to maintenance treatment. We used the HRSD-17 to measure the total burden or residual symptoms. We defined the presence of residual core mood symptoms as a score of ≥1 on the HRSD-17 core symptom subscale including the depressed mood (item 1), guilt (item 2), suicide (item 3), and anergia/anhedonia (item 7). Persistent insomnia was defined as a score of ≥1 on the HRSD-17 sleep subscale including the early (item 4), middle (item 5), and late (item 6) insomnia items. In addition to the HRSD-17 subscale, insomnia was assessed with the Pittsburgh Sleep Quality Index (Buysse et al. 1989). Persistent anxiety was defined as a score of ≥2 on the HRSD-17 anxiety subscale including the agitation (item 9), psychic (item 10) and somatic (item 11) anxiety, and hypochondriasis (item 15). These factor-analytically derived subscales have been shown to explain similar proportions of overall symptom variability (Dombrovski et al. 2006). Their construction was confirmed by the results of a recent meta-analysis of the

Depress Anxiety. Author manuscript; available in PMC 2009 July 6.
HRSD-17 factor structure (Shafer 2006). We chose the above cutoffs rather than continuous subscale scores because of the limited internal consistency of the HRSD-17 subscales (Dombrovski et al. 2006; Dombrovski et al. 2007), probably reflecting insufficient unidimensionality of the scale as a whole (Bagby et al. 2004). We chose cutoffs of 1 on the core mood symptoms subscale (range 0–16) because any symptoms of depressed mood or anhedonia are clinically significant in a remitted patient, and on the sleep subscale, because sleep items are scored from 0 to 2, resulting in lower ratings overall (range 0–6). The cutoff of 2 on the anxiety subscale (range 0–14) was chosen because the psychic anxiety, somatic anxiety, and hypochondriasis items are scored from 0 to 4 and ratings of 1 correspond to doubtful symptoms or physiological phenomena resembling somatic anxiety. Our examination of score distributions at the start of maintenance treatment confirmed these cutoffs.

Data Analyses

We included data on all 131 randomized participants; PSQI scores were available on 76 (the scale was added later in the study). We used Cox proportional hazards regression models stratifying by SSRI treatment to examine the relationship between residual symptoms and subsequent recurrence. Symptom measures included the total residual symptom burden (HRSD-17 total score at the time of randomization), residual core mood, insomnia, and anxiety symptom subsets (HRSD-17 subscales and PSQI score at the time of randomization). Data were censored at the time of discontinuation for patients who terminated from the study. Next, we tested whether identified predictors would remain significant after accounting for other known predictors of recurrence using a multiple Cox proportional hazards regression model. These predictors included age, number of previous episodes, and duration of the index episode.

RESULTS

Table 1 presents participant characteristics at the beginning of maintenance treatment. There were no differences between groups in overall severity of residual symptoms (t(129)=0.63, p=0.53), prevalence of core mood symptoms (Fisher’s exact p=0.31), insomnia (p=0.31), or anxiety symptoms (p=1.0) among participants requiring sequential treatment (IPT + SSRI) compared to participants recovered with IPT alone.

The HRSD total score was not significantly related to the hazard of recurrence (hazard ratio [HR]: 1.12, confidence interval [CI]: [0.99–1.26], p=0.064). Likewise, neither persistent core mood symptoms (HR: 1.09, CI: 0.54–2.21, p=0.81) nor persistent anxiety symptoms (HR: 1.39, CI: 0.68–2.81, p=0.37) significantly predicted recurrence risk.

By contrast, patients with persistent insomnia measured both by the HRSD-17 subscale (HR: 2.33, CI: 1.13–4.81, p=0.022) and the PSQI (HR: 1.25, CI: 1.02–1.53, p=0.030) were more likely to suffer a recurrence. The survival plot (Figure 1) illustrates that women with persistent insomnia who required sequential pharmacotherapy had the highest recurrence rate (65%, n=11/17, CI: 42%–87%) compared to women requiring sequential treatment without insomnia (13%, n=2/15, CI: 0–30%), women who had recovered with IPT alone but had persistent insomnia (21%, n=9/42, CI: 9%–34%) or no insomnia (18%, n=10/57, CI: 8%–27%). Persistent insomnia measured by the HRSD-17 subscale (HR: 2.48, CI: 1.19–5.17, p=0.015) and the PSQI (HR: 1.97, CI: 1.01–3.86, p=0.047) remained a significant predictor in a Cox multiple proportional hazards regression model, controlling for the duration of current episode and the number of previous episodes.

Having observed the long-term impact of insomnia, we examined post hoc whether it was present among women requiring sequential treatment before their antidepressant medication

Depress Anxiety. Author manuscript; available in PMC 2009 July 6.
was tapered. The prevalence of insomnia was 47– before and 53– after the antidepressant medication was discontinued (Fisher’s exact p=0.80).

DISCUSSION

Persistent insomnia, but not core depressive symptoms such as depressed mood, guilt, suicidal thoughts, and anergia/anhedonia, predicted depression-free survival during two-year maintenance treatment with interpersonal psychotherapy in women recovered from an episode of recurrent major depression. Contrary to our hypothesis, persistent anxiety symptoms had no such impact on long-term course.

Randomized controlled design, two-year follow-up, and comprehensive clinical characterization add confidence in our findings. The relatively low recurrence rate in our sample (26% percent in 99 remitters with IPT monotherapy and 50% in 32 remitters with sequential treatment) presumably reflect the protective effect of ongoing treatment; this may have limited our power to detect differences in time to recurrence between patients. Our use of HRSD-17 subscales to assess residual symptoms can be seen as another limitation, because of their relative lack of unidimensionality, characteristic of the HRSD-17 in general (Bagby et al. 2004; Dombrovski et al. 2007). To address this issue, we used clinically determined cutoffs to define significant levels of residual symptoms. The PSQI provided a more comprehensive assessment of sleep disturbance, independently validating our sleep results; however both instruments rely on self-report, and objective polysomnographic recordings were not obtained in our study. Our results can only be generalized to women with a history of recurrent depression, but no serious psychiatric comorbidities (other than anxiety disorders) treated in a specialty psychiatric clinic.

Effects of persistent insomnia on mood

Our finding of early recurrence of depression in women with persistent sleep problems agrees with previous clinical studies (Buysse et al. 1996; Dombrovski et al. 2007; Perlis et al. 1997; Reynolds et al. 1997) and with findings of insomnia preceding incident depression in community samples [(Johnson et al., 2006; Neckelmann et al., 2007; Weissman et al. 1997), ing, older studies reviewed in (Riemann and Voderholzer 2003)], underscoring the clinical importance of restoring normal sleep in depression. It is clear that in a subgroup of patients, even a combination of psychotherapy and SSRI does not achieve this goal; half of those women in our study reported some sleep problems following recovery from depression. Of even greater clinical interest may be the observation that IPT alone was not sufficient to maintain remission among patients who required medication treatment in addition to psychotherapy to recover from the depressive episode AND who still displayed persistent insomnia. This is in line with previous findings of poorer response to psychotherapy in depressed patients with abnormal sleep (Thase et al. 1996). It is possible that the need for acute antidepressant drug treatment and sleep problems that persist following remission are clinical markers of a biologically distinct depressive subtype that is characterized by hyperarousal and a recurrent or chronic course. Hyperarousal is a state of abnormally high alertness in the sleep environment characterized by the failure to appropriately modulate the metabolic activity of the prefrontal cortex (Nofzinger et al. 2004) and the brain’s electrical activity during sleep (Krystal et al. 2002; Merica et al. 1998; Perlis et al. 2001), by the sympathetic cardiovascular response (Bonnet and Arand 1997), hypercortisolemia (Rodentbeck et al. 2002; Vgontzas et al. 2001), and increased systemic metabolism (Bonnet and Arand 1995). Hyperarousal and, more broadly, disruption of the circadian cycle, appears to play a particularly important role in depressed women (Armitage 2007); it may interfere with mood regulation and thus precipitate new depressive episodes in these patients.
Role of persistent anxiety

In our study, women aged 20 to 60 with residual anxiety were not more likely to suffer an early depressive recurrence, unlike older participants in previous trials (Dombrovski et al. 2007; Flint and Rifat 1997). Our power to detect a possible relationship between persistent anxiety and recurrence of depression in this sample was limited by both the low rate of recurrence and the fact that stringent remission criteria (HRSD-17 ≤ 7) may have precluded some women with residual anxiety symptoms from being classified as remitters. Furthermore, as we have previously reported, patients with anxiety symptoms are less likely to respond acutely to IPT (Frank et al. 2000) and are probably under-represented in our sample. In addition, the 4-item HRSD-17 subscale may not be sensitive enough to all anxiety symptoms. However, this observation may point to actual differences in the phenomenology and course of depression across the lifespan: anxiety may play a greater role in old age than in mid-life, as noted by Kraepelin a century ago (Diefendorf 1915).

Treatment implications

Half of the women who did not initially respond to IPT alone in our study continued to suffer from poor sleep after the addition of fluoxetine. We do not know whether treating their sleep problems would have prevented early recurrence of depression. Future studies might test alternative treatment strategies for patients with depression complicated by persistent insomnia. Although tricyclic antidepressants (TCAs) have been largely replaced by newer drug classes because of their autonomic and cardiovascular side effects, their ability to improve not only insomnia (Haskell et al. 1975; Vaisanen et al. 1978; Young et al. 1976), but also sleep quality (Buysse et al. 1996; Feuillade et al. 1992; Hajak et al. 2001; Roth et al. 1982; Shipley et al. 1985) is well established. “Second-generation” sedating antidepressants trazodone and nefazodone (Manber et al. 2003; Thase et al. 2002) also improve sleep quality and provide another antidepressant monotherapy option for these patients, although their benefits need to be weighed against possible cardiovascular side effects of trazodone and the risk of hepatic failure, which resulted in the boxed warning for nefazodone. The new 5HT-2C antagonist agomelatine, which has shown antidepressant efficacy in initial short-term clinical trials (Kennedy and Emsley 2006; Loo et al. 2002; Pierre Olie and Kasper 2007), appears to exert effects on sleep quality and circadian rhythm mediated by its action on melatonin MT-1 and MT-2 receptors. Agomelatine may prove to be a useful antidepressant for patients with enduring sleep problems. The addition of a GABA-ergic hypnotic such as zolpidem (Asnis et al. 1999) or escopiclone (Fava et al. 2006) also appears to improve both sleep and mood outcomes in the short term, although the possibly increased incidence of depression on hypnotics (Kripke, 2007) warrants caution. Finally, cognitive behavioral therapy for insomnia (CBT-I), which combines behavioral approaches (relaxation training, stimulus control, sleep restriction) with a cognitive intervention targeting negative beliefs about sleep, is effective and may be superior to hypnotics in primary insomnia (Jacobs et al., 2004; Sivertsen et al., 2006). There is accumulating evidence, albeit so far limited to small studies (Kuo et al., 2001; Lichstein et al., 2000; Taylor et al. 2007), of its efficacy in insomnia associated with depression.

CONCLUSION

In summary, we found that women who required the addition of an antidepressant medication to achieve remission, and reported poor sleep following the recovery from an episode of recurrent major depression and cessation of the antidepressant, are less likely to remain well with maintenance psychotherapy alone. Future studies will be needed to determine the optimal acute and maintenance treatment regime for such patients; however, our findings suggest that maintenance psychotherapy alone is unlikely to be sufficient in this group.
Acknowledgments

Supported by: grants MH049115 and MH030915, and the John A. Hartford Foundation.

References


Depress Anxiety. Author manuscript; available in PMC 2009 July 6.


Kriipe DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007; 7:42. [PubMed: 17711589]


Kuo T, Manber R, Loewy D. Insomniacs with comorbid conditions depressions achieved comparable improvement in a cognitive behavioral group treatment program as insomniacs without comorbid depression. Sleep. 2001; 14(A62)


Depress Anxiety. Author manuscript; available in PMC 2009 July 6.


Figure 1.
Legend: Kaplan-Meyer depression-free survival plots illustrate that women who required sequential acute treatment and suffered from persistent insomnia measured by the HRSD-17 subscale had the highest recurrence rate (65%, n=17, CI: 42%–87%) compared to women requiring sequential treatment without insomnia (13%, n=15, CI: 0–30%), and to women who had recovered with IPT alone with (21%, n=42, CI: 9%–34%) or without persistent insomnia (18%, n=57, CI: 8%–27%).
## Table 1
Characteristics of women who started maintenance treatment

<table>
<thead>
<tr>
<th>Mean (SD) unless otherwise specified</th>
<th>Remitted with IPT alone N=99</th>
<th>Remitted with IPT+SSRI N=32</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>37.8 (10.4)</td>
<td>38.3 (9.9)</td>
</tr>
<tr>
<td>Race: n(%) white</td>
<td>87 (88%)</td>
<td>28 (88%)</td>
</tr>
<tr>
<td>Education in years</td>
<td>15.2 (1.8)</td>
<td>14.9 (2.0)</td>
</tr>
<tr>
<td>Married: n(%)</td>
<td>35 (35%)</td>
<td>17 (53%)</td>
</tr>
<tr>
<td>Employed fulltime: n(%)</td>
<td>59 (60%)</td>
<td>17 (53%)</td>
</tr>
<tr>
<td><strong>Clinical Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of current episode, wks</td>
<td>26.1 (20.8) median=20.0</td>
<td>29.9 (21.6) median=24.5</td>
</tr>
<tr>
<td>Number of previous episodes</td>
<td>4.6 (3.1) median=4</td>
<td>5.2 (2.6) median=5</td>
</tr>
<tr>
<td>Age of first lifetime onset</td>
<td>25.6 (9.1)</td>
<td>23.5 (8.8)</td>
</tr>
<tr>
<td><strong>Baseline Scores</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamilton Rating Scale for Depression-17 item</td>
<td>18.1 (2.7)</td>
<td>18.8 (3.2)</td>
</tr>
<tr>
<td>Global Assessment Scale</td>
<td>56.1 (4.7)</td>
<td>54.9 (5.2)</td>
</tr>
<tr>
<td>Beck Depression Inventory</td>
<td>24.7 (6.6)</td>
<td>26.1 (6.6)</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of acute and continuation treatment, weeks</td>
<td>26.9 (4.8)</td>
<td>56.3 (11.9)</td>
</tr>
<tr>
<td>Number of psychotherapy sessions before start of maintenance</td>
<td>22.0 (3.5)</td>
<td>47.3 (7.4)</td>
</tr>
<tr>
<td>Final dose of fluoxetine, mg/d (N=31)*</td>
<td>28.6 (15.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Residual symptoms at the start of maintenance treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRS17 total</td>
<td>3.24 (2.71)</td>
<td>3.59 (2.79)</td>
</tr>
<tr>
<td>%Core ≥ 1</td>
<td>45%</td>
<td>56%</td>
</tr>
<tr>
<td>%Sleep ≥ 1</td>
<td>42%</td>
<td>53%</td>
</tr>
<tr>
<td>%Anxiety ≥ 2</td>
<td>32%</td>
<td>31%</td>
</tr>
<tr>
<td>Pittsburgh Sleep Quality Index</td>
<td>4.14 (2.20)</td>
<td>3.82 (1.59)</td>
</tr>
</tbody>
</table>

* One patient received sertraline 100 mg/d